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Abstract We investigated the prevalence of neutralizing
antibodies (NA) to human Adenovirus (Ad) 5 both in
healthy subjects (HS) and Chronic Hepatitis B (CHB)
patients in Shanghai. Detection of anti-Ad5 NA (percent-
age of detection and titers) was similar between HS and
CHB patients. A high percentage of subjects harbored no
detectable antibodies (32.2 %) while proportion of subjects
displaying very high antibody titers was low (4 %). Neither
demographic factors (gender, age, health) nor AST/ALT or
HBV circulating DNA titers affected detection of Ad5-
specific NA. These observations pave the ground for
development of Ad5-based immunotherapeutics aiming at
treating CHB patients in China.






CHB Chronic Hepatitis B
AdC Chimpanzee adenovirus
HBV Hepatitis B virus
HCC Hepatocellular carcinoma




Adenovirus (Ad) vectors are extremely potent at inducing
cellular-based immune responses to the encoded immuno-
gens. They have been used to develop vaccines against a
range of infectious diseases including human immunode-
ficiency virus (HIV), as well as cancers [1]. Ad serotype 5
has been the most widely used Ad vector because of ear-
lier, historical development, its important safety profile and
its remarkable capacity to induce strong, long-lasting and
broad T-cell based immune responses, in particular
CD8? driven ones [2].
We have developed a novel immunotherapeutic TG1050
based on Ad5 that has been engineered to express three
major antigens or antigenic domains encoded by the Hepa-
titis B virus (HBV) genome: the core, polymerase and
HBsAg [3]. This novel therapeutics aims at improving
treatment of Chronic Hepatitis B (CHB) patients in partic-
ular at increasing cure rate. TG1050 has been shown in pre-
clinical studies to induce robust, broad, long-lasting as well
as cross-reactive T cells displaying characteristics similar to
those found in patients who resolve infection, together with
The data haven’t been presented at any meeting.
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early antiviral activity [3]. Because anti-vector pre-immu-
nity may have some effects on immunity mounted against
the vector-encoded immunogens, it is important to docu-
ment level of vector pre-immunity in the vaccine-targeted
population. A number of studies have documented important
geographic variations in the sero-prevalence of Ad5 ranging
from 40-70 % in the USA and Europe, to 90 % in various
regions of Africa and 95% in Thailand [4]. Recent publi-
cations indicate a prevalence in the range of 60-70 % in the
Chinese population [5–8]. Because Ad5-based immuno-
therapies may be of great value in the treatment of CHB in
countries displaying elevated prevalence of Hepatitis B, it is
important to evaluate whether infection by HBV may
influence anti-Ad5 sero-prevalence.
Recently, Jian et al. assessed the prevalence of NA to
chimpanzee adenovirus (AdC) serotypes 6 and 7 in healthy
adults, CHB patients and patients with primary hepato-
cellular carcinoma (HCC) in China. They demonstrated
that the sero-prevalence rate of AdC6 and AdC7 in CHB
patients and HCC patients were much higher than in
healthy subjects [9].
We compare here such prevalence of Ad5 NA in both
healthy subjects (HS) and CHB patients in subjects living
in Shanghai and vicinity.
Two hundred plasma samples from healthy donors, and
204 serum samples from age and gender matched CHB
outpatients from Ruijin hospital (Shanghai, China) were
collected. Subjects were divided into four age groups (See
Table 1A and B). Clinical parameters including HBV viral
load, Alanine transaminase (ALT) and Aspartate transam-
inase (AST) levels were collected.
Ad5-specific NA titers were measured using an adapted
luciferase-based virus neutralization assay described by
Sprangers et al. [10]. Briefly, diluted samples were mixed
with 1.33 9 107 viral particles (VP) of replication defec-
tive (E1 and E3 deleted) luciferase-expressing Ad vector
(ShenZhao Biotechnology, China), and incubated for 1
hour at room temperature. Five 9 104 A549 target cells
were added and incubated at 37 C, 5 % CO2. Following
24 h incubation, luciferase activity in the cells was quan-
tified using Luciferase Assay System (Promega) with a
Microplate Reader (BioTek). The 90 % neutralization
sample titer was determined to be the sample dilution
which resulted in 90 % neutralization of the Ad-luciferase
vector replication as tested on A549 cells. Ranges of titers
were defined as \ 20, 20-200, 201-1000, or [ 1000. They
were selected to give a qualitative representation of sub-
jects displaying negative, low, moderate or high pre-
existing anti-Ad5 immunity, respectively.
Due to the restrictions of sample collection, plasma
samples were collected from HS, while serum samples
were obtained from CHB patients. To exclude a potential
effect of the sample type on the sensitivity of detection of
Ad5 NA, we compared NA levels in serum or plasma of six
subjects. As anticipated, no difference was observed (data
not shown) supporting comparative analysis using either
type of samples.
Sero-prevalence was reported based on age, gender and
CHB infection status. In order to analyze impact of these
parameters on NA titers, all participants were split into
either negative (\ 20) versus positive (C 20) groups or into
negative and low titers (B 200) versus medium and
high titers ([ 200) groups. The distribution of patients in
these groups according to each demographic parameter was
tested using the Chi-Square test. Multivariate and univar-
iate logistic regressions were performed to calculate odds
ratios (OR) and 95 % confidence interval (CI) in each
demographic subgroup. Spearman’s correlation coefficients
were calculated to analyze correlation between clinical
parameters (ALT, ALT and HBV-DNA) and Ad5 NA
titers. Analyses were performed with the software SAS 9.3.
P-values \0.05 were considered significant.
The prevalence of Ad5 NA in plasma samples taken
from 200 HS in Shanghai from 20-55 years of age was
evaluated. As shown in Table 1A, 63.5% of HS (127/200)
displayed detectable anti-Ad5 NA (titers C 20). Overall,
23 % (46/200) and 36.5 % (73/200) of participants dis-
played low (20-200) or moderate (201-1000) NA titers,
respectively, while only 4 % (8/200) of individuals dis-
played high titers ([1000).
Anti-Ad5 sero-prevalence was concomitantly evaluated
in 204 age and gender matched CHB outpatients. As
shown in Table 1B, 72.06 % of CHB patients (147/204)
displayed anti-Ad5-specific NA, a rate similar to that seen
in HS. Twenty-six percent (53/204) and 42 % (86/204) of
patients displayed low (20-200) and moderate (201-1000)
levels of NA titers, while only 3.9 % (8/204) of them
displayed high NA titers ([ 1000).
When subjects were stratified on the basis of detection or
not of Ad5 NA, i.e. whether they displayed titers \ 20
or C 20, no difference was detected between HS and CHB
patients or between different age/gender groups (Table 2A).
Similarly, when stratification was made on a broader basis,
i.e., between subjects with negative or low titers B 200 ver-
sus medium and high titers [ 200, no statistical differences
could be observed within the groups compared (Table 2B).
A global statistical analysis was also performed to
evaluate the impact of different demographic parameters
including age, gender and CHB infection status on the sero-
prevalence of anti-Ad5 NA (Table 2). Multivariate and
univariate analyses of factors associated with Ad5 NA
titers are shown in Table 2C with associated odds ratios
(95 % CI) and p-values. None of the studied factors had
any significant effect on the levels of detected Ad5 NA
titers, either in subjects with titers \ 20 versus C 20 or in
subjects with titers B 200 versus [ 200 (Table 2).
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We examined whether there was a correlation between
clinical parameters such as HBV-DNA load, ALT and AST
levels (data not shown) and Ad5 NA titers in CHB patients.
Spearman’s correlation coefficients were used and showed
that levels of Ad5-specific NA titers were not significantly
correlated with these clinical parameters (Fig. 1).
Adenoviruses and in particular human Ad 5, have been
widely developed as vaccine vehicles because of their high
safety profile and their unique capacity to induce strong
T-cell based immunity [2]. In the field of HIV vaccine
development, high levels of NA to Ad5 have been shown to
lower detection of immunogen-specific induced immunity
following vaccination and/or to restrict the scope of epitope
detection [11, 12]. Contrary observations have been
reported more recently in studies of Ad5-based anti-
malaria and anti-tuberculosis vaccines [13, 14]. Although
these later studies were of low size (phase 1), the authors
reported a lack of effect of anti-Ad5 pre-immunity on
induction of immunogen-specific T-cells, observations that
are very encouraging for the development of non-HIV
Ad5-based vaccines. In China, at least one Ad5-based
immunotherapeutics has successfully reached the market,
supporting the value of the Ad5 platform [15]. An inter-
national epidemiological study by Mast et al. showed that
Ad5 NA titers vary according to geographic location, with
titers being higher in non-US and non-European countries
[4]. Recently, detailed studies have been reported on the
sero-prevalence of Ad5 NA in China [5–8]. In particular,
two studies have shown that 77.4 % of healthy adults in
Guangzhou and 72 % of healthy adults in six different
regions of China displayed detectable Ad5 NA [ 5,6]. In
agreement with the results of these studies and others
performed in China [5–7], we observed 63.5 % of sero-
prevalence to Ad5 NA in 200 HS from Shanghai. In
addition, we demonstrated that more than half (60%) of the
tested HS have negative or low titers of Ad5 NA (B 200),
while the proportion of high titers individuals ([ 1000)
was very low, only 4%. We confirmed that gender or age
difference did not significantly impact the level and titers
of Ad5 NA in HS. Because CHB infection is an important
and well-recognized medical concern in China [16], efforts
are ongoing to develop novel curative treatment regimens.
We have developed a novel Ad5-based immunotherapeutic
TG1050, which gathers important immunological features
found in resolvers [3]. The present study shows that
72.06% of CHB patients displayed detectable anti-Ad5 NA
titers, which, in their levels and distribution, are compa-
rable to those seen in HS (p [ 0.05).
We confirmed that a very small number of CHB patients
(3.92 %) display high NA titers ([ 1000). Interestingly,
our study did not reveal any correlation with HBV-DNA,
ALT, and AST levels and Ad5 NA titers. Overall, the
Table 1 Sero-prevalence of
Ad5 NA in healthy subjects
(A) and CHB patients (B)
Ad5 NA titer, no. (%)
< 20 ‡ 20 Overall
20-200 201-1000 > 1000 Total (‡ 20)
A.
Overall 73 (36.50) 46 (23.00) 73 (36.50) 8 (4.00) 127 (63.50) 200
Age, years
21-30 20 (40.00) 14 (28.00) 13 (26.00) 3 (6.00) 30 (60.00) 50
31-40 21 (42.00) 9 (18.00) 17 (34.00) 3 (6.00) 29 (58.00) 50
41-50 16 (32.00) 8 (16.00) 25 (50.00) 1 (2.00) 34 (68.00) 50
51-55 16 (32.00) 15 (30.00) 18 (36.00) 1 (2.00) 34 (68.00) 50
Sex
Male 37 (37.00) 23 (23.00) 39 (39.00) 1 (1.00) 63 (63.00) 100
Female 36 (36.00) 23 (23.00) 34 (34.00) 7 (7.00) 64 (64.00) 100
B.
Overall 57 (27.94) 53 (25.98) 86 (42.16) 8 (3.92) 147 (72.06) 204
Age, years
21-30 14 (28.00) 9 (18.00) 25 (50.00) 2 (4.00) 36 (72.00) 50
31-40 13 (26.00) 10 (20.00) 26 (52.00) 1 (2.00) 37 (74.00) 50
41-50 13 (25.49) 20 (39.22) 15 (29.41) 3 (5.88) 38 (74.50) 51
51-55 17 (32.08) 14 (26.42) 20 (37.74) 2 (3.77) 36 (67.92) 53
Sex
Male 32 (31.07) 24 (23.30) 43 (41.75) 4 (3.88) 71 (68.93) 103
Female 25 (24.75) 29 (28.71) 43 (42.57) 4 (3.96) 76 (75.25) 101
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Table 2 Distribution of Ad5-
specific NA titers
*P-value based on chi-square
test
A. Distribution of Ad5 NA titers (\ 20 vs C 20) according to clinical status (HS, CHB), age and gender
Ad5 NA titer, no. (%)
< 20 ‡ 20 Overall P-value*
Overall 130 274 404
Clinical status 0.066
Healthy subjects 73 (56.15) 127 (46.35) 200 (49.50)
CHB subjects 57 (43.85) 147 (53.65) 204 (50.50)
Age, years 0.841
20-30 34 (26.15) 66 (24.09) 100 (24.75)
31-40 34 (26.15) 66 (24.09) 100 (24.75)
41-50 30 (23.08) 74 (27.01) 104 (25.74)
51-55 32 (24.62) 68 (24.82) 100 (24.75)
Gender 0.475
Male 69 (53.08) 135 (49.27) 204 (50.50)
Female 61 (46.92) 139 (50.72) 200 (49.50)
B. Distribution of Ad5 NA titers (B 200 vs [ 200) according to clinical status (HS, CHB), age and gender
Ad5 NA titer, no. (%)
£ 200 > 200 Overall P-value*
Overall 229 175 404
Clinical status 0.258
Healthy subjects 119 (51.97) 81 (46.29) 200 (49.5)
CHB subjects 110 (48.03) 94 (53.71) 204 (50.50)
Age, years 0.800
20-30 57 (24.89) 43 (24.57) 100 (24.75)
31-40 53 (23.14) 47 (26.86) 100 (24.75)
41-50 59 (25.76) 45 (25.71) 104 (25.74)
51-55 60 (26.20) 40 (22.86) 100 (24.75)
Gender 0.784
Male 117 (51.09) 87 (49.71) 204 (50.50)
Female 112 (48.91) 88 (50.29) 200 (49.50)
C. Odds ratio and 95% confidence intervals of Ad5 NA titers (B 200 vs [ 200) according to clinical status
(HS, CHB), age and gender status, based on univariate and multivariate logistic regression
Univariate analysis
Effect OR [95%CI] P-value
Age
Age (31-40 vs 21-30) 0.85 [0.487 – 1.486] 0.390
Age (41-50 vs 21-30) 0.99 [0.568 – 1.722] 0.994
Age (51-55 vs 21-30) 1.13 [0.645 – 1.987] 0.440
Sex
Sex (Female vs Male) 0.95 [0.638 – 1.403] 0.784
Subject
Clinical status (CHB vs HS) 0.80 [0.537 – 1.182] 0.258
Multivariate analysis
Effect OR [95%CI] P-value
Sex (Female vs Male) 0.95 [0.637 – 1.403] 0.780
Age (31-40 vs 21-30) 0.85 [0.489 – 1.486] 0.386
Age (41-50 vs 21-30) 0.99 [0.570 – 1.730] 0.980
Age (51-55 vs 21-30) 1.13 [0.644 – 1.988] 0.444
Health (CHB vs HS) 0.80 [0.536 – 1.181] 0.256
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collected data indicate that CHB infection does not influ-
ence sero-prevalence and titers of Ad5 NA, implying that
chronic infection by HBV does not modulate neither pos-
itively nor negatively the development of NA to Ad5.
Obviously, it would be of interest to extend our study to
other regions in China, beyond the region of Shanghai.
It is difficult to strictly compare studies that have eval-
uated the presence and titers of Ad5 NA, as assays are not
universally standardized and vary from study to study [5–
8]. In our study, the proportion of individuals, either HS or
CHB patients in Shanghai, displaying high titers of Ad5
NA, was lower than that reported by Yu et al. A number of
reasons may explain the differences observed. Our studied
population was likely different from that studied by Yu
et al. [6], (different geographic location) and, for example,
may have included more migrant population (Shanghai is
known to have a large migrant population). It would be of
obvious interest to expand our analysis beyond the area of
Shanghai in order to generalize our observations to major
cities in China. In addition, in our study, Ad5-specific NA
titers were measured using chemiluminescence-based NA
test (CLNT), which has higher sensitivity than the fluores-
cence-based NA (FRNT) assay reported by Liu et al. [8]. Our
evaluation was primarily based on 90 % neutralization and
Fig. 1 Impact of clinical
parameters on Ad5 NA titers.
NA titers to Ad5 were
determined in sera from 204
CHB patients, and the
correlation between Ad5 NA
titers and ALT (Upper panel)
and HBV DNA level (Bottom
panel) was analyzed. Levels of
Ad5 NA titers, ALT and HBV
DNA were represented in
logarithmic values (log).
P values (based on Spearman’s
correlation) are indicated on the
graph
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not 50 % as often reported. Even when similar CLNT tests
are used [7, 9], different protocols (such as virus concen-
tration, cell density, etc.), use of different luminometers, and
different definitions of neutralization titers may all influence
the quality and sensitivity of detection assays, rendering
comparisons delicate to perform.
In conclusion, our study shows that the sero-prevalence
and titer of Ad5 NA are not affected by infection with
HBV, an observation supporting the development of
TG1050 in Chinese CHB infected patients.
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